{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:14:15Z","timestamp":1776698055600,"version":"3.51.2"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6_suppl_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1998,12]]},"DOI":"10.1212\/wnl.51.6_suppl_5.s2","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:37:26Z","timestamp":1336916246000},"source":"Crossref","is-referenced-by-count":82,"title":["Mechanism of Action of Intravenous Immunoglobulin and Therapeutic Considerations in the Treatment of Autoimmune Neurologic Diseases"],"prefix":"10.1212","volume":"51","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[{"name":"From the Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","first-page":"1","volume":"1","year":"1981","unstructured":"Imbach P, d'Apuzzo V, Hirt A, Rossi E, Vest M, Barandum S, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1128-1131.","journal-title":"Lancet"},{"key":"e_1_3_2_3_2","first-page":"2","volume":"112","year":"1990","unstructured":"Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-292.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201023260101"},{"key":"e_1_3_2_5_2","first-page":"7","volume":"126","year":"1997","unstructured":"Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 1997;126:721-730.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Gordon DS guest ed. Innovative use of intravenous immunoglobulin in clinical hematology. Am J Med 1987;83(4A):1-56.","DOI":"10.1016\/0002-9343(87)90551-1"},{"key":"e_1_3_2_7_2","first-page":"2","volume":"13","year":"1992","unstructured":"Jungi TW, Nydegger VE. Proposed mechanisms of action of intravenous IgG in autoimmune diseases. Transfus Sci 1992;13:267-290.","journal-title":"Transfus Sci"},{"key":"e_1_3_2_8_2","unstructured":"Eibl MM Wedgood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev 1989;1(Suppl):1-42."},{"key":"e_1_3_2_9_2","first-page":"2","volume":"44","year":"1994","unstructured":"Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.","journal-title":"Neurology"},{"key":"e_1_3_2_10_2","first-page":"2","volume":"121","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-262.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_11_2","first-page":"4","volume":"25","year":"1988","unstructured":"Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988;25:41-48.","journal-title":"Mol Immunol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.144.1.1"},{"key":"e_1_3_2_13_2","first-page":"5","volume":"88","year":"1991","unstructured":"Varela F, Andersson A, Dietrich G, et al. The population dynamics of antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991;88:5917-5921.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_14_2","first-page":"6","volume":"85","year":"1990","unstructured":"Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85:620-629.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Lecky BRF ed. Gammaglobulin treatment in neurology. Fundamentals and clinical applications. J Neurol Neurosurg Psychiatry 1994;57(Suppl 1).","DOI":"10.1136\/jnnp.57.Suppl.1"},{"key":"e_1_3_2_16_2","first-page":"7","volume":"139","year":"1994","unstructured":"Kazatchkine MD, Dietrich G, Hurez, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev 1994;139:79-107.","journal-title":"Immunol Rev"},{"key":"e_1_3_2_17_2","first-page":"3","volume":"137","year":"1986","unstructured":"Uher F, Dickler HB. Cooperativity between B lymphocytes membrane molecules: independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors downregulates B lymphocyte function. J Immunol 1986;137:3124-3129.","journal-title":"J Immunol"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)42297-6"},{"key":"e_1_3_2_19_2","first-page":"3","volume":"92","year":"1993","unstructured":"Vassilev T, Gelin C, Kaveri SV, Xilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-372.","journal-title":"Clin Exp Immunol"},{"key":"e_1_3_2_20_2","first-page":"6","volume":"48","year":"1997","unstructured":"Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology 1997;48S:64-69.","journal-title":"Neurology"},{"key":"e_1_3_2_21_2","first-page":"S","volume":"242","year":"1995","unstructured":"Motomura M, Bain PG, Misbah SA, et al. Effect of intravenous immunoglobulin (IVIg) treatment on anti-calcium channel antibody titres in the Lambert-Eaton myasthenic syndrome [abstract]. J Neurol 1995;242:S44.","journal-title":"J Neurol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390102"},{"key":"e_1_3_2_23_2","first-page":"1","volume":"139","year":"1996","unstructured":"Yuki N, Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM, antibody-mediated neuropathies. J Neurol Sci 1996;139:160-162.","journal-title":"J Neurol Sci"},{"key":"e_1_3_2_24_2","first-page":"2","volume":"33","year":"1993","unstructured":"Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-242.","journal-title":"Ann Neurol"},{"key":"e_1_3_2_25_2","first-page":"4","volume":"44","year":"1994","unstructured":"Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology 1994;44:429-432.","journal-title":"Neurology"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1994.00540130010001"},{"key":"e_1_3_2_27_2","first-page":"7","volume":"40","year":"1996","unstructured":"Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795.","journal-title":"Ann Neurol"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116550"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1994.tb00854.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307013290101"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.1.1"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37(S)74-86.","DOI":"10.1002\/ana.410370709"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)21001-4"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114127"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107043250101"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117294"},{"key":"e_1_3_2_37_2","unstructured":"Dalakas MC. Clinical relevance of IVIg in the modulation of the complement-mediated tissue damage: implications in dermatomyositis Guillain Barr\u00e9 syndrome and myasthenia gravis. In: Kazatchkine M Morel A eds. Intravenous immunoglobulin research and therapy. London: Parthenon Publishing 1996:89-93."},{"key":"e_1_3_2_38_2","unstructured":"Dalakas MC. Experience with IVIg in the treatment of inflammatory myopathies. In: Kazatchkine M Morel A. eds. Intravenous immunoglobulin research and therapy. London: Parthenon Publishing 1996;275-284."},{"key":"e_1_3_2_39_2","first-page":"2","volume":"71","year":"1996","unstructured":"Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain Barr\u00e9 syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol 1996;71:227-229.","journal-title":"J Neuroimmunol"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1995;37(Suppl):2-13.","DOI":"10.1002\/ana.410370703"},{"key":"e_1_3_2_41_2","first-page":"2","volume":"77","year":"1986","unstructured":"Kurlander RJ, Hall J. Comparison of intravenous gamma-globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986;77:2010-2018.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_42_2","first-page":"7","volume":"66","year":"1980","unstructured":"Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980;66:773-781.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_43_2","first-page":"3","volume":"89","year":"1992","unstructured":"Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T cell receptor 20 chain. Proc Natl Acad Sci USA 1992;89:3325-3329.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_44_2","first-page":"6","volume":"91","year":"1993","unstructured":"Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91:602-607.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_45_2","first-page":"1","volume":"20","year":"1997","unstructured":"Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997;20:1102-1107.","journal-title":"Muscle Nerve"},{"key":"e_1_3_2_46_2","first-page":"3","volume":"71","year":"1994","unstructured":"Rigal D, Vermot-Desroches C, Heitz S, et al. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994;71:309-314.","journal-title":"Clin Immunol Immunopathol"},{"key":"e_1_3_2_47_2","first-page":"4","volume":"79","year":"1987","unstructured":"Leung DYM, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987;79:468-472.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_48_2","first-page":"7","volume":"341","year":"1993","unstructured":"Blasczyk R, Westhoff V, Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.","journal-title":"Lancet"},{"key":"e_1_3_2_49_2","first-page":"8","volume":"97","year":"1996","unstructured":"Kaveri S, Vassilev T, Hurex V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:868-869.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","unstructured":"van Engelson BGM Miller DJ Pavelko KD Hommes OR Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994;57(Suppl):65-68.","DOI":"10.1136\/jnnp.57.Suppl.65"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.1.1"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107043250101"},{"key":"e_1_3_2_54_2","first-page":"2","volume":"2","year":"1986","unstructured":"Woodruff RK, Griff AP, Firkin FL, Smith IL. Fatal thrombic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217-218.","journal-title":"Lancet"},{"key":"e_1_3_2_55_2","first-page":"2","volume":"42","year":"1992","unstructured":"Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.","journal-title":"Neurology"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.1.1"},{"key":"e_1_3_2_57_2","first-page":"6","volume":"61","year":"1990","unstructured":"Hague RA, Eden DB, Yap PL, Mok JYO, Rae P. Hyperviscosity in HIV infected children: a potential hazard during intravenous immunoglobulin therapy. Blut 1990;61:66-67.","journal-title":"Blut"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.2"},{"key":"e_1_3_2_59_2","first-page":"5","volume":"329","year":"1993","unstructured":"Constantinescu CS, Chang AP, McClusky LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:583-584.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_60_2","first-page":"3","volume":"122","year":"1995","unstructured":"Dalakas MC. Aseptic meningitis and intravenous immunoglobulin. Ann Intern Med 1995;122:316-317.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-1-199707010-00001"},{"key":"e_1_3_2_62_2","first-page":"1","volume":"1","year":"1982","unstructured":"Chan-Lam D, Fitzsimmons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet 1982;1:1436.","journal-title":"Lancet"},{"key":"e_1_3_2_63_2","first-page":"1","volume":"124","year":"1988","unstructured":"Boom BW, Brand A, Bavinek JB, et al. Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose immunoglobulin intravenously. Arch Dermatol 1988;124:1550-1553.","journal-title":"Arch Dermatol"},{"key":"e_1_3_2_64_2","first-page":"5","volume":"314","year":"1986","unstructured":"Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986;314:560-564.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00915419"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207023270101"},{"key":"e_1_3_2_67_2","first-page":"1","volume":"154","year":"1994","unstructured":"Asham N, Palmer BF, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-1987.","journal-title":"Arch Intern Med"},{"key":"e_1_3_2_68_2","unstructured":"Blick KE Liles SM. Principles of clinical chemistry. New York: John Wiley & Sons 1985:401-404."},{"key":"e_1_3_2_69_2","first-page":"5","volume":"43","year":"1994","unstructured":"Outbreak of hepatitis C associated with intravenous immunoglobulin administration, United States, October 1993-June 1994. MMWR 1994;43:505-509.","journal-title":"MMWR"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199407073310101"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.51.6_Suppl_5.S2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T15:34:36Z","timestamp":1711640076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.51.6_Suppl_5.S2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":69,"journal-issue":{"issue":"6_suppl_5","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["10.1212\/WNL.51.6_Suppl_5.S2"],"URL":"https:\/\/doi.org\/10.1212\/wnl.51.6_suppl_5.s2","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}